Get the Stockscreener App
54.99
3.27%
1.74
Korro Bio Inc Stock (KRRO) Latest News
Korro Bio, Inc Receives Approval from the Australian Bellberry Human Research Ethics Committee and Clearance from the Australian Therapeutic Goods Administration to Initiate A Phase 1/2A Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency - Marketscreener.com
Korro Bio's SWOT analysis: RNA editing stock poised for growth amid AATD treatment race - Investing.com
HC Wainwright Reaffirms Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World
Korro Bio (NASDAQ:KRRO) Trading 9.3% HigherHere's What Happened - MarketBeat
Korro Bio (NASDAQ:KRRO) Receives Buy Rating from HC Wainwright - MarketBeat
Korro to Participate in Upcoming Investor Conferences - The Manila Times
Korro Bio CEO to Present at Major Healthcare Conferences in December | KRRO Stock News - StockTitan
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency - The Manila Times
Korro Bio Gains Approval for Phase 1/2a AATD Treatment Trial, Shows Strong Preclinical Data | KRRO Stock News - StockTitan
Jones Trading bullish on Korro Bio stock amid RNA editing and AATD prospects - Investing.com
Jones Trading Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation - MSN
Korro Bio FY2024 EPS Forecast Increased by HC Wainwright - MarketBeat
William Blair Has Positive View of Korro Bio FY2024 Earnings - MarketBeat
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Eventide Asset Management's Strategic Reduction in Korro Bio Inc Holdings - GuruFocus.com
Deep Track Capital, LP's Strategic Acquisition of Korro Bio Inc Shares - GuruFocus.com
Korro to Present at the Jefferies London Healthcare Conference - The Manila Times
Korro Bio to Present RNA-Editing Breakthroughs at Jefferies London Healthcare Conference | KRRO Stock News - StockTitan
Korro Bio’s Progress and Financial Updates - TipRanks
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for growth - Investing.com
William Blair Reiterates "Outperform" Rating for Korro Bio (NASDAQ:KRRO) - MarketBeat
Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
FMR LLC Reduces Stake in Korro Bio Inc - GuruFocus.com
Korro Bio CFO Vineet Agarwal sells $56,000 in stock - Investing.com
Korro Bio CFO Vineet Agarwal sells $56,000 in stock By Investing.com - Investing.com UK
Korro Bio Partners with Novo Nordisk, Reports $169M Cash Position Despite Widening Losses | KRRO Stock News - StockTitan
4 Biotech Stocks With AI, Machine Learning Prowess - Investing.com
Korro Bio (NASDAQ:KRRO) Stock Price Up 10.9%Here's What Happened - MarketBeat
Korro Bio files in Australia to begin first-in-human study of KRRO-110 for AATD - BioWorld Online
Korro Bio (NASDAQ:KRRO) Shares Gap DownHere's Why - MarketBeat
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board - The Manila Times
Korro Bio, Inc. Announces Submission to Bellberry HREC for Phase 1/2 Clinical Study of KRRO-110 for AATD - Marketscreener.com
Korro Bio (NASDAQ:KRRO) Trading Down 5.1%Time to Sell? - MarketBeat
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap - Investing.com India
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap By Investing.com - Investing.com South Africa
Korro Bio (NASDAQ:KRRO) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Korro Bio (NASDAQ:KRRO) Coverage Initiated at Raymond James - Defense World
RBC lifts Korro Bio stock target on positive RNA editing outlook - Investing.com Australia
Raymond James Initiates Coverage of Korro Bio (KRRO) with Strong Buy Recommendation - MSN
Korro Bio price target raised to $105 from $95 at RBC Capital - TipRanks
RBC lifts Korro Bio stock target on positive RNA editing outlook By Investing.com - Investing.com South Africa
Royal Bank of Canada Boosts Korro Bio (NASDAQ:KRRO) Price Target to $105.00 - MarketBeat
Korro Bio initiated with a Strong Buy at Raymond James - TipRanks
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. - Investor's Business Daily
Korro bio CFO Vineet Agarwal sells $799,526 in stock - Investing.com India
Insider Selling: Korro Bio, Inc. (NASDAQ:KRRO) CFO Sells 10,216 Shares of Stock - MarketBeat
Korro bio CFO Vineet Agarwal sells $799,526 in stock By Investing.com - Investing.com Australia
Korro Bio shares target lifted, buy rating on RNA editing potential - Investing.com
Korro Bio (NASDAQ:KRRO) Trading Down 4.1%Should You Sell? - MarketBeat
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):